BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Yan Xu, Aditi Sharma, Yang Chen, Honghui Zhou. What We Can Learn from Current Inflammatory Bowel Disease (IBD) Biological Therapy—Dose Regimen and OthersCurrent Pharmacology Reports 2019; 5(3): 115 doi: 10.1007/s40495-019-00180-x
2
Elena Milanesi, Maria Dobre, Teodora E. Manuc, Gabriel Becheanu, Cristian G. Tieranu, Elena M. Ionescu, Mircea Manuc. Mucosal gene expression changes induced by anti‐TNF treatment in inflammatory bowel disease patientsDrug Development Research 2019; 80(6): 831 doi: 10.1002/ddr.21566
3
Stuart Bloom, Tariq Iqbal, Chuka Nwokolo, Vipul Jairath, Jesse Hall, Bruce Dzyngel, Peter Gardzinski. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Influence of Immunosuppressants at BaselineAmerican Journal of Gastroenterology 2019; 114(Supplement): S419 doi: 10.14309/01.ajg.0000592388.53875.b2
4
Tushar Shukla, Bruce E. Sands. Novel Non-biologic Targets for Inflammatory Bowel DiseaseCurrent Gastroenterology Reports 2019; 21(5) doi: 10.1007/s11894-019-0689-2
5
Cindy CY Law, Deborah Koh, Yueyang Bao, Vipul Jairath, Neeraj Narula. Risk of postoperative infectious complications from medical therapies in inflammatory bowel diseaseCochrane Database of Systematic Reviews 2019;  doi: 10.1002/14651858.CD013256
6
Irene Marafini, Silvia Sedda, Vincenzo Dinallo, Giovanni Monteleone. Inflammatory cytokines: from discoveries to therapies in IBDExpert Opinion on Biological Therapy 2019; 19(11): 1207 doi: 10.1080/14712598.2019.1652267
7
Peter Kienle. Impact of Modern Drug Therapy on Surgery: Crohn's DiseaseVisceral Medicine 2018; 34(6): 422 doi: 10.1159/000495127
8
Pharmacokinetic Profiling and Simultaneous Determination of Thiopurine Immunosuppressants and Folic Acid by Chromatographic MethodsMolecules 2019; 24(19): 3469 doi: 10.3390/molecules24193469
9
Boris Gole, Uroš Potočnik. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology AnalysisCells 2019; 8(6): 515 doi: 10.3390/cells8060515
10
Sara Salvador-Martín, Beatriz López-Cauce, Olga Nuñez, Emilio J. Laserna-Mendieta, María I. García, Elena Lobato, Judith Abarca-Zabalía, María Sanjurjo-Saez, Alfredo J. Lucendo, Ignacio Marín-Jiménez, Luis A. Menchén, Luis A. López-Fernández. Genetic predictors of long-term response and trough levels of infliximab in crohn’s diseasePharmacological Research 2019; 149: 104478 doi: 10.1016/j.phrs.2019.104478
11
Young-Jae Hwang, Seung-Joo Nam, Wanjoo Chun, Song In Kim, Sung Chul Park, Chang Don Kang, Sung Joon Lee, Partha Mukhopadhyay. Anti-inflammatory effects of apocynin on dextran sulfate sodium-induced mouse colitis modelPLOS ONE 2019; 14(5): e0217642 doi: 10.1371/journal.pone.0217642
12
Ciro Romano, Sergio Esposito, Roberta Ferrara, Giovanna Cuomo. Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditionsExpert Opinion on Biological Therapy 2019; : 1 doi: 10.1080/14712598.2020.1689953